GLP-1 drugs like Ozempic are transforming weight loss, but a new UVA study warns they're not improving a critical measure of ...

The persistent threat of reciprocal tariffs from US President Donald Trump has resulted in many trade deals, while the IMF ...

Cosmetic surgeons are reporting a growing number of patients with sagging skin and facial hollowing after losing weight with ...

ASX companies such as LTR Pharma are finding smarter ways to stretch the value of existing assets and launch into broader ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Explore the U.S. new F-47 fighter jet and its potential impact on global military balance, including reactions from Russia ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

Seeking Alpha's roundup of statements, announcements and remarks that could impact markets, sectors or individual stocks.

Novo Nordisk lowers 2025 guidance as Wegovy and Ozempic face slower U.S. uptake, competition, and continued compounded GLP-1 ...

Bagsværd, Denmark, 29 July 2025 - Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of 2025 and updated full-year sales and opera ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.